Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 198412, 6 pages
Clinical Study

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series

1Division of Medical Oncology C, Centro di Riferimento Oncologico, 33081 Aviano, Italy
2Epidemiology Unit, Centro di Riferimento Oncologico, 33081 Aviano, Italy
3Clinical Trial Office, Centro di Riferimento Oncologico, 33081 Aviano, Italy
4Pharmacy Unit, Centro di Riferimento Oncologico, 33081, Aviano, Italy

Received 26 October 2011; Revised 5 January 2012; Accepted 20 January 2012

Academic Editor: Bruno Vincenzi

Copyright © 2012 Vincenzo Di Lauro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Trastuzumab-based regimes improved clinical outcome in women with overexpressing HER2 metastatic breast cancer, mainly due to the availability of different combination therapies, clinically active and well tolerated. In this study we retrospectively evaluated clinical activity and toxicity of trastuzuamb plus gemcitabine regimen in heavily pretreated HER2 positive metastatic breast cancer patients. Although the observed population was heavily pretreated, the evaluated regimen was notably effective in terms of response rate, time to progression and survival, with very mild toxicity. These data suggest that in over expressing HER2 metastatic breast cancer patients, sequential trastuzumab based chemotherapeutic regimens can achieve good response rate with prolonged TTP in responding patients, even after other target therapy such as lapatinib based combinations.